The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
Abstract
Summary: Thalidomide and immunomodulatory drugs (IMiDs), which target multiple myeloma (MM) cells and the bone marrow microenvironment, can overcome drug resistance. These agents also have immunomodulatory effects. Specifically, we have reported that thalidomide increased serum interleukin‐2 (IL‐2) levels and natural killer (NK) cell numbers in the peripheral blood of responding MM patients. In this study, we investigated the mechanisms whereby IMiDs augment NK cell cytotoxicity. NK cytotoxicity and antibody‐dependent cell‐mediated cytotoxicity (ADCC) of peripheral blood mononuclear cells cultured with IMiDs were examined in the presence or absence of anti‐IL‐2 antibody, ciclosporin A or depletion of CD56‐positive cells. IMiDs‐induced signalling pathways, triggering IL‐2 transcription in T cells, were also delineated. IMiDs facilitated the nuclear translocation of nuclear factor of activated T cells‐2 and activator protein‐1 via activation of phosphoinositide‐3 kinase signalling, with resultant IL‐2 secretion. IMiDs enhanced both NK cell cytotoxicity and ADCC induced by triggering IL‐2 production from T cells. These studies defined the mechanisms whereby IMiDs trigger NK cell‐mediated tumour‐cell lysis, further supporting their therapeutic use in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
Direct Regulation of the Akt Proto-Oncogene Product by Phosphatidylinositol-3,4-bisphosphate
Franke, T. F., Kaplan, D. R., Cantley, L. C., & Toker, A. (1997) · Science · doi:10.1126/science.275.5300.665 · Cited by 1,460
Thurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1669 · Cited by 1,226
Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 913
Self-citationNF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Self-citationNatural killer cells, viruses and cancer
Cerwenka, A., & Lanier, L. L. (2001) · Nature Reviews Immunology · doi:10.1038/35095564 · Cited by 875
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Self-citationRichardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citation
Cited by
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Quach, H., Ritchie, D., Stewart, A. K., Neeson, P., Harrison, S., Smyth, M. J., & Prince, H. M. (2010) · Leukemia · doi:10.1038/leu.2009.236 · Cited by 600
Prospects for the use of NK cells in immunotherapy of human cancer
Ljunggren, H.-G., & Malmberg, K.-J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2073 · Cited by 543
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805762 · Cited by 535
Self-citation
Metadata
- Authors
- Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., Raje, N., Kumar, S., Chauhan, D., Treon, S. P., Richardson, P., & Anderson, K. C.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2004-12-02
- Volume
- 128
- Issue
- 2
- Pages
- 192-203
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2012959199
- Cited by
- 323
- References
- 49
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. https://app.cochat.ai/papers/10.1111/j.1365-2141.2004.05286.x
- The paper
- Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., Raje, N., Kumar, S., Chauhan, D., Treon, S. P., Richardson, P., & Anderson, K. C. (2005). Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2004.05286.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.